Análisis de la acción Prestige Consumer Healthcare Inc (PBH)PBHPrestige Consumer Healthcare Inc

Prestige Consumer Healthcare Inc. develops, manufactures, markets, sells and distributes over-the-counter (OTC) health and personal care products to mass merchandisers, drug/drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Breathe Right nasal strips, Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart treatments, Little Remedies pediatric over-the-counter products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment, Debrox earwax remover, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Prestige Consumer Healthcare Inc is currently trading at $47.80, which is significantly below the analyst price targets of $72 and $65. However, the stock has a low RSI of 42.46, indicating it is nearing oversold conditions, but the recent 5-day change of -4.25% and a year-to-date decline of -21.92% suggest caution. The upcoming earnings report on November 5 could be a potential catalyst for a rebound, but the company faces risks with a high net leverage of approximately 4.0x EBITDA from its recent acquisition, which could pressure its financials if not managed properly.

7 analysts cover PBH: 5 rate it Buy, 2 Hold and 0 Sell. The average price target is 76.00.